Contrast enhancement agent for magnetic resonance imaging

• US 6,972,122 B2
• Filed: 12/18/2001
• Issued: 12/06/2005
• Est. Priority Date: 01/05/2001
• Status: Expired due to Fees

• Current Assignee: Duke University, Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Original Assignee: Duke University, Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Inventors: Dewhirst, Mark W., Neeman, Michal, Greenberg, Charles S., Haroon, Zishan
• Primary Examiner(s): Tate, Christopher R.
• Assistant Examiner(s): CHISM, BILLY D
• Application Number:
  US10/025,698
• Publication Number:
  US 20020136692A1
• Time in Patent Office: 1,449 Days
• Field of Search: 424/9.1, 514/16, 514/2, 514/13, 514/14, 514/15, 530/329, 530/324, 530/325
• US Class Current: 424/9.1
• CPC Class Codes: A61K 49/085 conjugated systems
• CPC Class Codes: A61K 49/14 Peptides, e.g. proteins
• CPC Class Codes: G01N 33/4905 Determining clotting time of blood by chemical methods G01N33/86, C12Q1/56

Abstract

Imaging agents for magnetic resonance imaging are disclosed. Methods of monitoring angiogenesis and the growth and remission of tumor tissue are also disclosed. Methods of monitoring blood clot formation and dissolution are additionally disclosed. Methods of monitoring wound healing are further disclosed. A kit for obtaining an image of a biological structure is further disclosed.

Claims

1. A contrast enhancement agent useful for providing a visible image of a biological sample comprising:

(a) at least one peptide comprising the amino acid sequence NXEQVSP (SEQ ID NO;

     1), wherein X is an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;

(b) at least one paramagnetic metal ion; and

(c) at least one chelator.

2. The contrast enhancement agent of claim 1, wherein the paramagnetic metal ion is selected from the group consisting of transition, lanthanide and actinide elements.

3. The contrast enhancement agent of claim 2, wherein the paramagnetic metal ion is selected from the group consisting of Gd(III), Mn(II), Cu(II), Cr(III), Fe(II), Fe(III), Co(II), Er(II), Ni(II), Eu(III) and Dy(III).

4. The contrast enhancement agent of claim 1, wherein the chelator is selected from the group consisting of DTPA, substituted DTPA, DOTA, substituted DOTA, EDTA, substituted EDTA, CDTA and substituted CDTA.

5. The contrast enhancement agent of claim 1, wherein the peptide comprises the amino acid sequence NXEQVSP (SEQ ID NO:

1), wherein X is an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;

the paramagnetic metal ion is gadolinium; and

the chelator is DTPA.

6. The contrast enhancement agent of claim 1, wherein the peptide comprises the amino acid sequence NGEQVSP (SEQ ID NO:

3), the paramagnetic metal ion is gadolinium and the chelator is DTPA.

7. The contrast enhancement agent of claim 1, wherein the agent is in lyophilized form.

8. A kit for obtaining a visible image of a biological sample comprising a two-vial system of a lyophilized contrast enhancement agent and an aqueous diluent, comprising:

(a) a first vial comprising a lyophilized contrast enhancement agent, wherein the agent comprises;

(i) a peptide comprising the amino acid sequence NXEQVSP (SEQ ID NO;

     1), wherein X is an amino acid selected from the group consisting of alanine, arginine, asparagines, aspartic acid, cysteine, glutamic acid, glycine, Histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;

(ii) at least one paramagnetic metal ion; and

(iii) at least one chelator; and

(b) a second vial comprising a pharmaceutically acceptable diluent.

9. The kit of claim 8, wherein the lyophilized contrast enhancement agent comprises gadolinium, DTPA and a peptide comprising the sequence NXEQVSP (SEQ ID NO:

1), wherein X is an amino acid selected from the group consisting of alanine, arginine, asparagines, aspartic acid, cysteine, glutamic acid, glycine, Histidine, isoleucine, leucine, lysine, methionine, phenylalanine, praline, serine, threonine, tryptophan, tyrosine, and valine; and

the pharmaceutically acceptable diluent comprises phosphate buffer saline.

10. A contrast enhancement agent useful for providing a visible image of a biological sample comprising:

(a) a peptide consisting of the amino acid sequence NXEQVSP (SEQ ID NO;

     1), wherein X is any amino acid;

(b) at least one paramagnetic metal ion; and

(c) at least one chelator.

11. The contrast enhancement agent of claim 10, wherein the paramagnetic metal ion is selected from the group consisting of transition, lanthanide and actinide elements.

12. The contrast enhancement agent of claim 11, wherein the paramagnetic metal ion is selected from the group consisting of Gd(III), Mn(II), Cu(II), Cr(III), Fe(II), FeCIII), Co(II), Er(II), Ni(II), Eu(III) and Dy(III).

13. The contrast enhancement agent of claim 10, wherein the chelator is selected from the group consisting of DTPA, substituted DTPA, DOTA, substituted DOTA, EDTA, substituted EDTA, CDTA and substituted CDTA.

14. The contrast enhancement agent of claim 10, wherein the peptide has the amino acid sequence NQEQVSP (SEQ ID NO:

2);

the paramagnetic metal ion is gadolinium; and

the chelator is DTPA.

15. The contrast enhancement agent of claim 10, wherein the agent is in lyophilized form.